• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌新辅助化疗后腋窝降阶梯处理用于治疗晚期淋巴结受累。

Axillary de-escalation after neoadjuvant chemotherapy for advanced lymph node involvement in breast cancer.

机构信息

Department of Surgery, Beth Israel Deaconess Medical Center - Harvard Medical School Boston, MA, USA.

Department of Surgery, Beth Israel Deaconess Medical Center - Harvard Medical School Boston, MA, USA; School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA.

出版信息

Am J Surg. 2024 Oct;236:115893. doi: 10.1016/j.amjsurg.2024.115893. Epub 2024 Aug 9.

DOI:10.1016/j.amjsurg.2024.115893
PMID:39153469
Abstract

INTRODUCTION

Sentinel lymph node biopsy reduces morbidity in patients with clinically node-positive breast cancer who achieve axillary pathologic complete response following neoadjuvant therapy (NACT). De-escalation trials primarily addressed cN1 disease, with underrepresentation of cN2 disease. This study evaluates the role of de-escalation in patients with cN2 breast cancer.

METHODS

A retrospective analysis of the National Cancer Database (2013-2020) included women over 18 with T1-2 invasive breast cancer and clinical N2 disease who received NACT followed by ALND or SLNB then ALND. The primary outcome was pathologic nodal status post-NACT.

RESULTS

Of 5852 cN2 patients treated, 18.15 ​% achieved ypN0, 0.97 ​% had isolated tumor cells, 19.14 ​% were ypN1, 49.64 ​% were ypN2, and 12.20 ​% were ypN3 following NACT. Achieving ypN0 was associated with pCR in the breast, HER2-positive and triple-negative receptor status, cT2 tumors, and younger age.

CONCLUSION

Despite some patients with cN2 disease achieving ypN0, most exhibited residual axillary disease post-NACT. These findings indicate that axillary de-escalation may not be feasible for most patients with cN2 disease, underscoring the importance of meticulous patient selection and assessment.

摘要

简介

前哨淋巴结活检可降低接受新辅助化疗(NACT)后腋窝病理完全缓解的临床阳性淋巴结乳腺癌患者的发病率。降阶梯试验主要针对 cN1 疾病,而 cN2 疾病代表性不足。本研究评估了降阶梯策略在 cN2 乳腺癌患者中的作用。

方法

对国家癌症数据库(2013-2020 年)进行回顾性分析,纳入接受 NACT 后行腋窝清扫术(ALND)或前哨淋巴结活检(SLNB)加 ALND 的 T1-2 浸润性乳腺癌且临床 N2 疾病的年龄大于 18 岁的女性患者。主要结局是 NACT 后的病理淋巴结状态。

结果

5852 例 cN2 患者中,18.15%达到ypN0,0.97%有孤立肿瘤细胞,19.14%为 ypN1,49.64%为 ypN2,12.20%为 ypN3。达到 ypN0 与乳腺 pCR、HER2 阳性和三阴性受体状态、cT2 肿瘤和较年轻的年龄相关。

结论

尽管一些 cN2 疾病患者达到了 ypN0,但大多数患者在 NACT 后仍存在腋窝残留疾病。这些发现表明,对于大多数 cN2 疾病患者,腋窝降阶梯可能不可行,这突显了对患者进行仔细选择和评估的重要性。

相似文献

1
Axillary de-escalation after neoadjuvant chemotherapy for advanced lymph node involvement in breast cancer.乳腺癌新辅助化疗后腋窝降阶梯处理用于治疗晚期淋巴结受累。
Am J Surg. 2024 Oct;236:115893. doi: 10.1016/j.amjsurg.2024.115893. Epub 2024 Aug 9.
2
Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival-a propensity score cohort study.新辅助化疗前后 cN0 期乳腺癌前哨淋巴结活检:对腋窝发病率和生存的影响——倾向评分队列研究。
Breast Cancer Res Treat. 2024 Jul;206(1):131-141. doi: 10.1007/s10549-024-07274-1. Epub 2024 Apr 18.
3
Axillary Management Following Neoadjuvant Chemotherapy in Clinically Node-Positive Breast Cancer.新辅助化疗后临床淋巴结阳性乳腺癌的腋窝处理。
Clin Breast Cancer. 2024 Aug;24(6):527-532. doi: 10.1016/j.clbc.2024.05.008. Epub 2024 May 21.
4
Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.新辅助治疗后乳腺癌腋窝分期中靶向腋窝清扫技术的可行性和验证:确定结果。
Surg Oncol. 2021 Sep;38:101636. doi: 10.1016/j.suronc.2021.101636. Epub 2021 Jul 21.
5
Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?新辅助治疗后达到病理完全缓解的临床 N2 期三阴性或 HER2 阳性乳腺癌患者行腋窝淋巴结清扫术是否必要?
Breast. 2024 Feb;73:103671. doi: 10.1016/j.breast.2024.103671. Epub 2024 Jan 5.
6
Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.新辅助化疗后前哨淋巴结活检中腋窝放射性碘种子埋置对阳性淋巴结乳腺癌的诊断准确性。
JAMA Surg. 2022 Nov 1;157(11):991-999. doi: 10.1001/jamasurg.2022.3907.
7
Prediction of the number of positive axillary lymph nodes according to sentinel lymph node involvement and biological subtypes in patients receiving neoadjuvant chemotherapy.根据新辅助化疗患者前哨淋巴结受累和生物亚型预测腋窝阳性淋巴结的数量。
BMC Surg. 2024 Jul 19;24(1):213. doi: 10.1186/s12893-024-02500-5.
8
Axillary management and long-term oncologic outcomes in breast cancer patients with clinical N1 disease treated with neoadjuvant chemotherapy.腋窝管理和新辅助化疗治疗临床 N1 期乳腺癌患者的长期肿瘤学结局。
World J Surg Oncol. 2024 Jul 29;22(1):199. doi: 10.1186/s12957-024-03477-4.
9
Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?对于 HER2 和三阴性乳腺癌等化疗敏感型肿瘤的 N2 乳腺癌患者,我们能否避免腋窝淋巴结清扫术?
Breast Cancer Res Treat. 2021 Feb;185(3):657-666. doi: 10.1007/s10549-020-05970-2. Epub 2020 Oct 17.
10
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.新辅助化疗后前哨淋巴结阳性乳腺癌患者的前哨淋巴结手术:ACOSOG Z1071(Alliance)临床试验。
JAMA. 2013 Oct 9;310(14):1455-61. doi: 10.1001/jama.2013.278932.